Unsynchronized butyrophilin molecules dictate cancer cell evasion of Vγ9Vδ2 T-cell killing

被引:6
|
作者
Wu, Zeguang [1 ]
Lamao, Qiezhong [1 ]
Gu, Meichao [1 ]
Jin, Xuanxuan [1 ]
Liu, Ying [1 ]
Tian, Feng [1 ]
Yu, Ying [1 ]
Yuan, Pengfei [2 ]
Gao, Shuaixin [3 ]
Fulford, Thomas S. [4 ]
Uldrich, Adam P. [4 ,5 ]
Wong, Catherine C. L. [6 ]
Wei, Wensheng [1 ]
机构
[1] Peking Univ, Genome Editing Res Ctr,State Key Lab Prot & Plant, Biomed Pioneering Innovat Ctr,Sch Life Sci, Beijing Adv Innovat Ctr Genom,Peking Tsinghua Ctr, Beijing 100871, Peoples R China
[2] EdiGene Inc, Life Sci Pk, Beijing 102206, Peoples R China
[3] Peking Univ, Hlth Sci Ctr, Ctr Precis Med Multi Res, Beijing 100191, Peoples R China
[4] Univ Melbourne, Dept Microbiol & Immunol, Peter Doherty Inst Infect & Immun, Parkville, Vic 3010, Australia
[5] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic, Australia
[6] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, State Key Lab Complex Severe & Rare Dis, Dept Med Res Ctr,Clin Res Inst,Peking Tsinghua Ctr, Beijing 100871, Peoples R China
基金
中国国家自然科学基金;
关键词
Butyrophilin; V gamma 9V delta 2 T-cell; Cancer-specific immune evasion; Glutaminyl-peptide cyclotransferase-like; Pyrophosphate metabolite; Immunotherapy; PHOSPHORYLATED ANTIGENS; ACTIVATION; GENES; BTN3A1; STIMULATION; RFX; TCR;
D O I
10.1038/s41423-024-01135-z
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
V gamma 9V delta 2 T cells are specialized effector cells that have gained prominence as immunotherapy agents due to their ability to target and kill cells with altered pyrophosphate metabolites. In our effort to understand how cancer cells evade the cell-killing activity of V gamma 9V delta 2 T cells, we performed a comprehensive genome-scale CRISPR screening of cancer cells. We found that four molecules belonging to the butyrophilin (BTN) family, specifically BTN2A1, BTN3A1, BTN3A2, and BTN3A3, are critically important and play unique, nonoverlapping roles in facilitating the destruction of cancer cells by primary V gamma 9V delta 2 T cells. The coordinated function of these BTN molecules was driven by synchronized gene expression, which was regulated by IFN-gamma signaling and the RFX complex. Additionally, an enzyme called QPCTL was shown to play a key role in modifying the N-terminal glutamine of these BTN proteins and was found to be a crucial factor in V gamma 9V delta 2 T cell killing of cancer cells. Through our research, we offer a detailed overview of the functional genomic mechanisms that underlie how cancer cells escape V gamma 9V delta 2 T cells. Moreover, our findings shed light on the importance of the harmonized expression and function of gene family members in modulating T-cell activity.
引用
收藏
页码:362 / 373
页数:12
相关论文
共 50 条
  • [21] ABCA1: AN UNEXPECTED ROLE IN Vγ9Vδ2 T-CELL ACTIVATION BY DENDRITIC CELLS
    Massaia, M.
    Riganti, C.
    Foglietta, M.
    Tripoli, E.
    Castella, B.
    HAEMATOLOGICA, 2018, 103 : S38 - S38
  • [22] RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor
    Sebestyen, Zsolt
    Scheper, Wouter
    Vyborova, Anna
    Gu, Siyi
    Rychnavska, Zuzana
    Schiffler, Marleen
    Cleven, Astrid
    Cheneau, Coraline
    van Noorden, Martje
    Peigne, Cassie-Marie
    Olive, Daniel
    Lebbink, Robert Jan
    Oostvogels, Rimke
    Mutis, Tuna
    Schuurhuis, Gerrit Jan
    Adams, Erin J.
    Scotet, Emmanuel
    Kuball, Jurgen
    CELL REPORTS, 2016, 15 (09): : 1973 - 1985
  • [23] Vγ9Vδ2 T cell activation by strongly agonistic nucleotidic phosphoantigens
    Morgane Moulin
    Javier Alguacil
    Siyi Gu
    Asmaa Mehtougui
    Erin J. Adams
    Suzanne Peyrottes
    Eric Champagne
    Cellular and Molecular Life Sciences, 2017, 74 : 4353 - 4367
  • [24] Vγ9Vδ2 T cell activation by strongly agonistic nucleotidic phosphoantigens
    Moulin, Morgane
    Alguacil, Javier
    Gu, Siyi
    Mehtougui, Asmaa
    Adams, Erin J.
    Peyrottes, Suzanne
    Champagne, Eric
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2017, 74 (23) : 4353 - 4367
  • [25] In vitro effects of aminobisphosphonates on Vγ9Vδ2 T cell activation and differentiation
    Ferlazzo, V.
    Sferrazza, C.
    Caccamo, N.
    Di Fede, G.
    Di Lorenzo, G.
    D'Asaro, M.
    Meraviglia, S.
    Dieli, F.
    Rini, G.
    Salerno, A.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2006, 19 (02) : 309 - 317
  • [26] Opportunities and challenges in development of phosphoantigens as Vγ9Vδ2 T cell agonists
    Wiemer, David F.
    Wiemer, Andrew J.
    BIOCHEMICAL PHARMACOLOGY, 2014, 89 (03) : 301 - 312
  • [27] Inhibition of human Vγ9Vδ2 T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer
    Emilie Lesport
    Jeremy Baudhuin
    Sylvie Sousa
    Joel LeMaoult
    Alessia Zamborlini
    Nathalie Rouas-Freiss
    Edgardo D. Carosella
    Benoit Favier
    Cellular and Molecular Life Sciences, 2011, 68 : 3385 - 3399
  • [28] Inhibition of human Vγ9Vδ2 T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer
    Lesport, Emilie
    Baudhuin, Jeremy
    Sousa, Sylvie
    LeMaoult, Joel
    Zamborlini, Alessia
    Rouas-Freiss, Nathalie
    Carosella, Edgardo D.
    Favier, Benoit
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2011, 68 (20) : 3385 - 3399
  • [29] Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
    Le Floch, Anne-Charlotte
    Imbert, Caroline
    Boucherit, Nicolas
    Gorvel, Laurent
    Fattori, Stephane
    Orlanducci, Florence
    Le Roy, Aude
    Archetti, Lorenzo
    Crescence, Lydie
    Panicot-Dubois, Laurence
    Dubois, Christophe
    Vey, Norbert
    Briantais, Antoine
    Anastasio, Amandine
    Cano, Carla
    Guittard, Geoffrey
    Frechin, Mathieu
    Olive, Daniel
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (12) : 1677 - 1690
  • [30] Development of V γ 9V δ 2T cell based chemo-immunotherapy in bladder cancer
    Shimizu, Teruki
    Tomogane, Mako
    Miyashita, Masatsugu
    Sano, Yusuke
    Shimizu, Daiki
    Ukimura, Osamu
    Ashihara, Eishi
    CANCER SCIENCE, 2018, 109 : 433 - 433